Investigational Drug Information for PF-04457845
✉ Email this page to a colleague
What is the drug development status for PF-04457845?
PF-04457845 is an investigational drug.
There have been 10 clinical trials for PF-04457845.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2009.
The most common disease conditions in clinical trials are Marijuana Abuse, Osteoarthritis, Knee, and Disease. The leading clinical trial sponsors are Pfizer, Yale University, and National Institute on Drug Abuse (NIDA).
Summary for PF-04457845
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 8 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2009-11-01) |
| Vendors | 41 |
Recent Clinical Trials for PF-04457845
| Title | Sponsor | Phase |
|---|---|---|
| Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) | Columbia University | Phase 2 |
| Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) | Johns Hopkins University | Phase 2 |
| Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) | Medical University of South Carolina | Phase 2 |
Clinical Trial Summary for PF-04457845
Top disease conditions for PF-04457845
Top clinical trial sponsors for PF-04457845
US Patents for PF-04457845
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
